Trial Profile

A Phase 1 Randomized, Double-Blind, Two Part Study of the Safety, Tolerability, Pharmacokinetics, Analgesic and Respiratory Effect of KUR-101 in Healthy Adult Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KUR-101 (Primary) ; Oxycodone
Indications Acute pain; Opioid-related disorders
Focus Adverse reactions; Therapeutic Use
Sponsors Kures

Most Recent Events

23 Dec 2022 Updated results published in the ATAI Life Sciences Media Release.
12 Dec 2022 Status changed from recruiting to completed.
20 Oct 2022 According to an a ATAI Life Sciences media release, data from this study will be webcasted live on Tuesday, October 25, 2022, at 12:00 PM ET.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com